We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanopore-based miRNA Analysis Detects Early Stage Bile Duct Cancer

By LabMedica International staff writers
Posted on 29 Jun 2022
Print article
Image: Pattern recognition of miRNA expression using DNA-computing and nanopore decoding (Photo courtesy of Ryuji Kawano, Tokyo University of Agriculture and Technology)
Image: Pattern recognition of miRNA expression using DNA-computing and nanopore decoding (Photo courtesy of Ryuji Kawano, Tokyo University of Agriculture and Technology)

A recent paper described a nanopore-based method for detecting microRNA expression patterns characteristic for bile duct cancer.

Bile duct cancer (cholangiocarcinoma) is an often lethal type of cancer, since by the time of diagnosis most bile duct cancers are already incurable. Thus, methods for the early diagnosis of this cancer are urgently needed.

Adopting a novel approach for early diagnosis of bile duct cancer, investigators at Tokyo University of Agriculture and Technology (Japan) developed a method for detecting microRNA (miRNA) expression patterns from liquid biopsy samples using nanopore-based DNA computing technology.

Using nanopore sequencing, a single molecule of DNA or RNA can be sequenced without the need for PCR amplification or chemical labeling of the sample. The magnitude of the electric current density across a nanopore surface depends on the nanopore's dimensions and the composition of DNA or RNA that is occupying the nanopore. Sequencing is made possible because, passing through the channel of the nanopore, the samples cause characteristic changes in the density of the electric current flowing through the nanopore. Nanopore sequencing has the potential to offer relatively low-cost genotyping, high mobility for testing, and rapid processing of samples with the ability to display results in real-time.

In the current study, a diagnostic DNA with a hairpin structure (HP-dgDNA), which had the ability to detect multiple miRNAs simultaneously, was employed as the computational molecule. The dgDNA was passed through a nanopore, and as the molecule transited the pore, bound miRNAs were “unzipped” from the DNA, resulting in a current inhibition of characteristic amplitude and duration. These perturbations in the current through the pore were measured and used to deduce the properties of the passing molecule.

Using this system of DNA-computing combined with nanopore decoding, the investigators identified the expression patterns of five different types of miRNAs (miR-193, miR-106a, miR-15a, miR-374, and miR-224). These miRNAs were over expressed in bile duct cancer. Moreover, the dgDNA–miRNA complexes could be detected at the attomolar (10–18 M) level, which was a significant improvement compared to previously reported limits of detection (about 10–12 M) for similar analytical platforms.

“DNA computing uses the biochemical reactions of the information-encoding DNA molecules to solve problems based on formal logic, in the same way that normal computers do,” said senior author Dr. Ryuji Kawano, professor of biotechnology and life science at Tokyo University of Agriculture and Technology. “In this case, a diagnostic DNA molecule was designed to be able to bind five different kinds of miRNA associated with bile duct cancer. In the process of binding the miRNA molecules, the diagnostic DNA converts the expression pattern of the miRNAs into the information contained in the form of a nucleic acid structure.”

The nanopore technique was described in the June 26, 2022, online edition of the journal JACS Au.

Related Links:
Tokyo University of Agriculture and Technology 

 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.